Takeda Ventures was joined in the series B round by venture firms Triathlon Medical Venture Partners and New Science Ventures, which co-led the round. The Global Cardiovascular Innovation Center and venture firms
Japan-based pharmaceutical group Takeda’s corporate venturing unit has helped Juventas Therapeutics, a US-based regenerative medicine company, raise $22.2m.
Takeda Ventures was joined in the series B round by venture firms Triathlon Medical Venture Partners and New Science Ventures, which co-led the round. The Global Cardiovascular Innovation Center and venture firms
Fletcher Spaght Ventures, Reservoir Venture Partners and Early Stage Partners, Venture Investors, Tri-State Growth Fund, Glengary and angel investors also participated.
Last year, Juventas Therapeutics spun-off from SironRX Therapeutics to…
